ATE228129T1 - Benzylaminochinuclidinen mit ein durch ein heteronom substituiertes alkyl als substanz p antagoniste - Google Patents

Benzylaminochinuclidinen mit ein durch ein heteronom substituiertes alkyl als substanz p antagoniste

Info

Publication number
ATE228129T1
ATE228129T1 AT94914619T AT94914619T ATE228129T1 AT E228129 T1 ATE228129 T1 AT E228129T1 AT 94914619 T AT94914619 T AT 94914619T AT 94914619 T AT94914619 T AT 94914619T AT E228129 T1 ATE228129 T1 AT E228129T1
Authority
AT
Austria
Prior art keywords
alkyl
alkoxy
pct
hydrogen
independently
Prior art date
Application number
AT94914619T
Other languages
English (en)
Inventor
Kunio Satake
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE228129T1 publication Critical patent/ATE228129T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
AT94914619T 1993-05-19 1994-05-13 Benzylaminochinuclidinen mit ein durch ein heteronom substituiertes alkyl als substanz p antagoniste ATE228129T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11710293 1993-05-19
PCT/JP1994/000781 WO1994026740A1 (en) 1993-05-19 1994-05-13 Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists

Publications (1)

Publication Number Publication Date
ATE228129T1 true ATE228129T1 (de) 2002-12-15

Family

ID=14703456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914619T ATE228129T1 (de) 1993-05-19 1994-05-13 Benzylaminochinuclidinen mit ein durch ein heteronom substituiertes alkyl als substanz p antagoniste

Country Status (12)

Country Link
US (1) US5741797A (de)
EP (1) EP0699199B1 (de)
AT (1) ATE228129T1 (de)
AU (1) AU6691094A (de)
CA (1) CA2161886C (de)
DE (1) DE69431751T2 (de)
DK (1) DK0699199T3 (de)
ES (1) ES2184762T3 (de)
FI (1) FI942314A (de)
IL (1) IL109646A0 (de)
PT (1) PT699199E (de)
WO (1) WO1994026740A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508837A (ja) * 1994-11-10 1998-09-02 ファイザー・インコーポレーテッド 眼の疾患を治療するためのｎｋ−１レセプターアンタゴニスト
ES2180693T3 (es) 1995-12-21 2003-02-16 Pfizer 3-((bencil 5-sustituido)amino)-2-fenilpiperidinas como antagonistas de la sustancia p.
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
SK252004A3 (sk) * 2001-07-20 2005-03-04 Pfizer Products Inc. Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov
AU2003243353A1 (en) * 2002-05-29 2003-12-19 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2006020049A2 (en) 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
RU2624045C2 (ru) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (de) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
RU2660349C2 (ru) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US20210309688A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
UA26401C2 (uk) * 1991-05-22 1999-08-30 Пфайзер Інк. Заміщеhі 3-аміhохіhуклідиhи
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
JPH07110850B2 (ja) * 1991-06-20 1995-11-29 フアイザー・インコーポレイテツド 窒素含有複素環化合物のフルオロアルコキシベンジルアミノ誘導体
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5294744A (en) * 1993-04-20 1994-03-15 Pfizer Inc. Formylation process for aromatic aldehydes
JP3326489B2 (ja) * 1996-02-10 2002-09-24 好高 青山 部品供給ロッド装置とそれによる供給方法
JPH09221677A (ja) * 1996-02-14 1997-08-26 Kansai Coke & Chem Co Ltd 石炭の高温予熱方法
JPH09319064A (ja) * 1996-05-29 1997-12-12 Konica Corp 写真製品の生産方法及び生産装置

Also Published As

Publication number Publication date
FI942314A (fi) 1994-11-20
WO1994026740A1 (en) 1994-11-24
IL109646A0 (en) 1994-08-26
FI942314A0 (fi) 1994-05-18
ES2184762T3 (es) 2003-04-16
US5741797A (en) 1998-04-21
EP0699199A1 (de) 1996-03-06
EP0699199B1 (de) 2002-11-20
DE69431751D1 (de) 2003-01-02
PT699199E (pt) 2003-01-31
DE69431751T2 (de) 2003-04-03
DK0699199T3 (da) 2002-12-16
AU6691094A (en) 1994-12-12
CA2161886A1 (en) 1994-11-24
CA2161886C (en) 1999-12-07

Similar Documents

Publication Publication Date Title
ATE228129T1 (de) Benzylaminochinuclidinen mit ein durch ein heteronom substituiertes alkyl als substanz p antagoniste
YU128091A (sh) Derivati hinuklidina
ES2169760T3 (es) Pirazoles sustituidos en 3,4 para el tratamiento de la inflamacion.
FI944394A (fi) Kinuklidiinijohdannaisia P-aineen antagonisteina
ES530901A0 (es) Procedimiento para preparar derivados de piperazina
ES2070175T3 (es) Derivados de acido 4-oxoquinolino-3-carboxilico, su preparacion y su uso.
ES2093399T3 (es) Nuevos derivados de acido fosfono-succinico, procedimiento para su preparacion y medicamentos que contienen estos compuestos.
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
SE8301412D0 (sv) Substituerade 1h-pyrazolo(1,5)pyrimidiner och forfarande for deras framstellning
ES493922A0 (es) Procedimiento para la preparacion de 4-fenoxipiperidinas
IL79841A0 (en) Heterocyclic compounds,their production and pharmaceutical compositions containing them
GB1426028A (en) 2-oxazoline derivatives
ZA905044B (en) New azetidines,their preparation and their application as intermediates for the preparation of compounds with antimicrobial activity
DK0434807T3 (da) Heteroaryl-3-oxopropannitrilderivater, der er nyttige til stimulering af myelopoiesis
DK294883A (da) Fremgangsmaade til fremstilling af alfa-alkylpolyolefincarboxylsyrer
SE7706346L (sv) Bensaminderivat
NO924634L (no) Nye oksazolderivater, deres fremstilling samt preparater inneholdende forbindelsene
DK0561863T3 (da) Amidiske derivater af glutamin-, asparagin- og 2-aminoadipinsyrer med antigastrin-virkning
MX9709465A (es) Derivados de bencimidazol 2-sustituidos como inhibidores de la proliferacion de celulas del musculo liso.
GR78456B (de)
SE7908024L (sv) Heterocykliska foreningar
ATE278676T1 (de) Imdazol-derivate, deren herstellung und deren verwendung als s-adenosylmethionin decarboxylase (=samdc) inhibitoren
ATE172458T1 (de) 1,5-benzodiazepin-derivate verwendbar als cck oder gastrin antagonisten
DK356287D0 (da) 2,6-piperazindionderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
DK156563C (da) Analogifremgangsmaade til fremstilling af carbacyklinderivater

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0699199

Country of ref document: EP

REN Ceased due to non-payment of the annual fee